GlassScriptPhysician profile
Thomas Tennant
NPI 1487725610
$1,462.56
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $793 · 2020: $457 · 2021: $16.10 · 2022: $197.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $212.00 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $199.14 | 2019-2020 | |
| Novo Nordisk INC | $116.64 | 2019-2021 | |
| Gilead Sciences, INC. | $100.02 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $92.98 | 2019 | |
| Pfizer INC. | $92.69 | 2019-2020 | |
| Amarin Pharma, INC. | $87.28 | 2019-2022 | |
| Abbvie INC. | $72.00 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.87 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $49.71 | 2019-2020 | |
| Neos Therapeutics, LP | $39.62 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.63 | 2019-2020 | |
| Genentech USA, INC. | $33.91 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.09 | 2022 | |
| Allergan, INC. | $27.33 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $23.41 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.63 | 2022 | |
| Lupin INC. | $18.30 | 2019 | |
| Optinose US, INC. | $17.43 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.61 | 2020 | |
| Shire North American Group INC | $16.43 | 2019 | |
| Aytu Biopharma, INC. | $13.60 | 2019 | |
| Dynavax Technologies Corporation | $13.47 | 2019 | |
| Acclarent, INC | $12.89 | 2019 | |
| Currax Pharmaceuticals LLC | $11.67 | 2020 | |
| Bausch Health US, LLC | $11.66 | 2020 | |
| Glaxosmithkline, LLC. | $11.22 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Tennant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.